The 10 Most Overhyped Supplements of 2026

Sea moss has zero clinical trials in humans for any of its wellness claims. Tongkat ali and turkesterone both face-planted in 2024 RCTs. NMN reliably raises blood NAD+ — and reliably fails to do anything else. The TikTok-to-trial-data gap, in 10 entries.

1. Sea moss (Irish moss) — Zero human trials for the wellness claims. Independent testing found iodine up to 47 mg/g (300× the RDA) plus regular heavy-metal contamination. Efficacy 1/5.
2. Turkesterone / Ecdysteroids — Two 2024–25 RCTs (Smith and Wilborn): no effect on muscle, strength, or body fat. The "natural anabolic" doesn't anabolize.
3. Fadogia agrestis — Zero human trials. Animal studies actually flagged testicular toxicity at the doses popular online.
4. Shilajit (Mumie) — 2023 Indian government test of 73 retail samples: ~40% exceeded permissible limits for lead, arsenic, or mercury.
5. Tongkat ali — 2024 RCT (n=109): no measurable change in testosterone, libido, or strength versus placebo.
6. NMN / NAD+ precursors — Reliably raises blood NAD+ 2–4×. The 2025 Prokopidis meta-analysis found no functional gains in older adults.
7. Spermidine — Entire human longevity evidence base is a single 60-person pilot. Marketed as autophagy insurance anyway.
8. Urolithin A — One published 2024 trial. ~$60/month for proprietary "Mitopure." Premium pricing on preliminary evidence.
9. Lion's mane mushroom — 2025 acute crossover RCT in young adults: no cognitive or mood benefit on standardised tests.
10. Apigenin — Popularised by longevity influencers at 50–100 mg/day. Most human trials use far lower flavonoid intakes; dose-response not characterised.

Bottom line

Marketing budgets aren't a substitute for trials. Six of the supplements above launched on a single positive paper or zero human data; several have since had RCTs that quietly failed. If a supplement's biggest selling point is its podcast appearances, treat it as a hypothesis, not a treatment.

See the full breakdown with efficacy scores and citations on Discover →